Assumed per-patient cost (US $) of projected TB interventions by country group.

Notes: Stated amounts reflect unit costs in US$ as of 2010, of (i) diagnosing and treating one TB patient under DOTS [1] and (ii) the additional cost incurred if the patient has multi-drug resistant (MDR) TB as estimated in the WHO/Stop TB partnership Global Plan to Stop TB 2011–2015 [1], and (iii) the additional cost incurred if the patient is HIV-positive and receives antiretroviral therapy (ART) for the duration of a 6-month DOTS course [47]. Costs are inflated at 3% per annum. Regional cost estimates were based on country cost estimates, weighted by each country’s notified incident cases.说明：所列金额为截至2010年的美元计价单位成本，涵盖以下三项：(i) 采用直接督导下短程疗法（Directly Observed Treatment, Short-course, DOTS）诊断与治疗1例结核病（Tuberculosis, TB）患者的成本[1]；(ii) 若患者罹患耐多药结核病（multi-drug resistant TB, MDR-TB），所需额外支出的医疗成本——该成本估算值源自《世界卫生组织/遏制结核病伙伴组织2011–2015年全球遏制结核病计划》[1]；以及(iii) 若患者HIV呈阳性且在6个月DOTS疗程期间接受抗逆转录病毒治疗（antiretroviral therapy, ART），所需额外支出的医疗成本[47]。所有成本均按每年3%的速率进行通胀调整。区域成本估算以各国成本估算值为基础，以各国通报的新发发病病例数为权重进行加权计算。